Teva Pharmaceutical stock (US88162G1031): Goldman Sachs conference puts New York-listed TEVA back in focus

Teva Pharmaceutical gained a new same-day catalyst after the company said CEO Richard Francis will join a fireside chat at the Goldman Sachs Global Healthcare Conference. The New York-listed stock remains active on the NYSE and TASE, keeping the focus on U.S. and Israeli trading venues.

Teva Pharmaceutical drew fresh attention on 06/02/2026 after the company said Chief Executive Richard Francis will take part in a fireside chat at the Goldman Sachs Global Healthcare Conference, a same-day update from the issuer's investor-relations page for the NYSE and TASE-listed stock. The announcement gives TEVA a new home-market catalyst in the United States even as investors also watch the Israeli listing and the company's latest trading profile in New York.

The stock traded at 22.10 USD on 06/02/2026 on the NYSE, according to Teva's investor-relations site, while the latest company update points to continued visibility with the global healthcare investor base through Goldman Sachs. In Germany, the stock was also available via Tradegate in EUR terms, but the home-country reference point for this article remains the United States and the primary listing venue in New York.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: TEVA
• Sector/industry: Pharmaceuticals, with a focus on generic medicines and specialty treatments
• Headquarters/country: Tel Aviv, Israel
• Core markets: United States, Europe, Israel, and other international markets
• Key revenue drivers: Generics, specialty medicines, and select branded therapies
• Home exchange/listing venue: NYSE and TASE (TEVA)
• Trading currency: USD

Teva Pharmaceutical: core business model

Teva develops, manufactures, and markets medicines across generics, specialty drugs, and branded products, with the United States remaining the single most important trading and commercial reference point for the company.

Latest quarterly results for Teva Pharmaceutical at a glance

Teva's most recent investor update in the supplied search set is the 06/02/2026 conference announcement, while the company has also highlighted a 2025 revenue base of $17.3 billion in a separate 2026 market recap, showing that the business is still being framed around scale, product mix, and execution in generics and branded medicines. That backdrop matters because any investor presentation by management tends to be read alongside the latest operating trend, even when no fresh earnings release is published on the same day.

According to the linked market recap, branded drugs accounted for 50% of 2025 sales, up from 43% in 2024, which suggests the portfolio mix has continued shifting toward higher-value products.

Conclusion

The Goldman Sachs conference appearance gives Teva a fresh same-day catalyst, and the stock's New York listing keeps the key reference point in the United States. With the latest available figures pointing to a larger branded-drug mix, the market will be watching whether management uses the event to reinforce that transition.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.